Topics:
Breast Cancer • Radiation Oncology
When do you offer PMRT for clinical T3N0 breast cancer with a pCR after neoadjuvant chemotherapy?
Would extensive residual DCIS (>5cm), hormone receptor negativity, Her2+ status, or age < 40 effect your decision?
Answer from: Radiation Oncologist at Academic Institution
I think this is a very interesting question, and one about which we have relatively little data. For pathologic T3N0 disease treated with mastectomy, radiotherapy is reasonable (NCCN tells us to "consider RT") but, I believe, falling out of favor. Data from the NSABP suggest that the 10-year risk of...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I think you need to look at the constellation of risk factors in addition to stage. Pathologic complete response in patients with clinical stage II disease is in general associated with a low local recurrence risk and many of these patients can avoid PMRT. However, there are other risk factors for...